XML 42 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share-Based Payments - SOP 2015 (Details) - SOP 2015 - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Jun. 23, 2017
Aug. 25, 2016
Sep. 23, 2015
Apr. 02, 2015
Options            
Outstanding at beginning of year (in shares) 3,044,899          
Forfeited (in shares) (29,050)          
Outstanding at end of year (in shares) 3,015,849          
Vested and exercisable at end of year (in shares) 1,337,202          
Weighted average exercise price in $ per share            
Outstanding balance at beginning of year (in dollars per share) $ 8.35          
Forfeited (in dollars per share) 7.49          
Outstanding balance at end of year (in dollars per share) 8.35          
Vested and exercisable balance at end of year (in dollars per share) $ 7.88          
Aggregate intrinsic value            
Aggregate intrinsic value, outstanding $ 3          
Aggregate intrinsic value, vested and exercisable 1          
Additional disclosures            
Share-based compensation expense $ 900 $ 700        
Options            
Share-Based Payments            
Vesting period 4 years          
Exercise period 10 years          
Additional disclosures            
Weighted-average remaining contractual life 8 years 2 months 12 days          
Total unrecognized compensation related to non-vested options (in dollars) $ 8,900          
Period of recognition of total unrecognized compensation related to options 1 year 2 months 12 days          
Options | First year            
Share-Based Payments            
Vesting period 1 year          
Percentage that vests during the period 25.00%          
Options | Second, third, and fourth years            
Share-Based Payments            
Percentage that vests during the period 75.00%          
Monthly vesting percentage 2.083%          
Nabriva Therapeutics plc ("Nabriva Ireland") | Redomiciliation Transaction | Ordinary Shares            
Share-Based Payments            
Number of shares to be awarded for each option when exercised     10      
Nabriva Therapeutics AG ("Nabriva Austria") | Common Stock            
Share-Based Payments            
Maximum number of shares authorized       346,235 177,499 95,000
Nabriva Therapeutics AG ("Nabriva Austria") | Redomiciliation Transaction | Common Stock            
Share-Based Payments            
Number of shares to be awarded for each option when exercised     1